Drugs最新文献_第7页

A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy. 腹腔化疗的临床药理学研究。

IF 13 1区医学

Drugs Pub Date : 2025-07-01 Epub Date: 2025-05-24 DOI: 10.1007/s40265-025-02195-9

Pascale C S Rietveld, Niels A D Guchelaar, Sebastiaan D T Sassen, Birgit C P Koch, Ron H J Mathijssen, Stijn L W Koolen

{"title":"A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy.","authors":"Pascale C S Rietveld, Niels A D Guchelaar, Sebastiaan D T Sassen, Birgit C P Koch, Ron H J Mathijssen, Stijn L W Koolen","doi":"10.1007/s40265-025-02195-9","DOIUrl":"10.1007/s40265-025-02195-9","url":null,"abstract":"Peritoneal metastases (PM), frequently observed in malignancies such as ovarian, colorectal, pancreatic, and gastric cancers, present a significant therapeutic challenge due to poor prognosis and limited effectiveness to systemic chemotherapy. The peritoneal-plasma barrier reduces effective drug transfer from plasma to the peritoneal cavity, reducing cytotoxic effects on PM. Intraperitoneal (IP) chemotherapy offers a locoregional approach, enabling high local drug concentrations that can enhance therapeutic efficacy while limiting systemic toxicity. The three major methods for IP administration-hyperthermic intraperitoneal chemotherapy (HIPEC), pressurized intraperitoneal aerosol chemotherapy (PIPAC), and catheter-based IP (CBIP) chemotherapy-each provide unique pharmacokinetic (PK) advantages for PM treatment. This review provides a comprehensive update on the pharmacological rationale of IP chemotherapy, focusing on drug characteristics that support extended IP retention and effective tumor targeting. The effects of administration variables are discussed, highlighting their role in optimizing IP drug exposure. Additionally, recent PK data on commonly used drugs in IP therapy, including platinum-based agents, taxanes, and novel nanoparticle formulations, will be evaluated. While PK rationale supports the administration of IP chemotherapy, further efficacy results from ongoing clinical trials are still awaited. Innovations in nanoparticle-based formulations and controlled-release systems offer substantial potential for improving both drug retention and targeted delivery, enhancing treatment precision and minimizing systemic toxicity. Continued exploration in these areas, along with optimization of IP administration protocols, is vital for advancing patient outcomes, refining therapeutic strategies, and maximizing the benefits of IP chemotherapy in clinical practice.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"931-943"},"PeriodicalIF":13.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vimseltinib: First Approval. 维姆塞替尼：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-07-01 Epub Date: 2025-05-26 DOI: 10.1007/s40265-025-02191-z

Arnold Lee

引用次数: 0

Catumaxomab: First Approval. Catumaxomab：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-07-01 Epub Date: 2025-04-30 DOI: 10.1007/s40265-025-02187-9

Yahiya Y Syed

引用次数: 0

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety. CPX-351在急性髓系白血病治疗中的作用：作用机制、疗效和安全性。

IF 13 1区医学

Drugs Pub Date : 2025-07-01 Epub Date: 2025-05-10 DOI: 10.1007/s40265-025-02194-w

Livio Pagano, Romano Danesi, Edoardo Benedetti, Riccardo Morgagni, Luigina Romani, Adriano Venditti

{"title":"The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety.","authors":"Livio Pagano, Romano Danesi, Edoardo Benedetti, Riccardo Morgagni, Luigina Romani, Adriano Venditti","doi":"10.1007/s40265-025-02194-w","DOIUrl":"10.1007/s40265-025-02194-w","url":null,"abstract":"CPX-351 (also known as VYXEOS® or Vyxeos liposomal) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin in a synergistic 5:1 molar ratio and was the first example that utilized CombiPlex®, a combination drug technology platform. Superior efficacy with CPX-351 in the pivotal phase 3 randomized clinical trial versus its conventional free-drug counterpart led to its approval for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes in multiple countries. Emerging evidence indicates that CPX-351 affords additional benefits compared with conventional chemotherapy, including protection against intestinal dysbiosis and fungal colonization, fewer infectious complications, and a lower incidence of cardiotoxicity. This review examines the mechanisms underlying CPX-351's therapeutic effects and highlights its expanding role in AML treatment by summarizing efficacy and safety data from preclinical models, the pivotal clinical trial, and real-world studies. Particular focus is given to recent findings on CPX-351's intestinal and cardioprotective properties, which together strengthen its safety and efficacy profile compared with conventional chemotherapy.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"855-866"},"PeriodicalIF":13.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mirdametinib: First Approval. 米达美替尼：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-07-01 Epub Date: 2025-05-27 DOI: 10.1007/s40265-025-02190-0

Sheridan M Hoy

引用次数: 0

Crinecerfont: First Approval. 罪犯：第一次批准。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.1007/s40265-025-02165-1

Arnold Lee

引用次数: 0

PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis. PI3K抑制剂作为COPD合并动脉粥样硬化的潜在治疗药物

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1007/s40265-025-02179-9

Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera

{"title":"PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis.","authors":"Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera","doi":"10.1007/s40265-025-02179-9","DOIUrl":"10.1007/s40265-025-02179-9","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) share a complex and multifactorial relationship characterized by overlapping risk factors, systemic inflammation, and intertwined pathophysiological mechanisms, with atherosclerosis emerging as a central inflammatory process connecting COPD and CVD, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. While systemic inflammation is recognized as a critical link between these conditions, the precise pathways through which inflammation arises remain under investigation. There is therefore a need for therapeutic strategies to mitigate cardiovascular risks in patients with COPD. Among the pathways contributing to this interplay, the phosphoinositide 3-kinase (PI3K) signaling pathway has gained significant attention. Dysregulated PI3K signaling contributes to inflammation, oxidative stress, and endothelial dysfunction, which are key drivers of both COPD and CVD. Consequently, PI3K inhibitors have emerged as a promising therapeutic approach to mitigate inflammation and oxidative damage, offering a targeted strategy to address the shared pathological mechanisms underlying these diseases. A comprehensive understanding of the role of PI3K signaling and its inhibitors could facilitate the development of novel interventions to reduce cardiovascular risk in patients with COPD.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"741-753"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of Centhaquine Citrate, a Selective Alpha-2B Adrenoceptor Agonist, in the Management of Circulatory Shock. 选择性α - 2b肾上腺素能受体激动剂柠檬酸氯喹治疗循环休克的潜力。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-20 DOI: 10.1007/s40265-025-02176-y

Matthieu Legrand, Amaresh Ranjan, Shruthi Rammohan, Daniel De Backer, Marlies Ostermann, Anil Gulati, Jean-Louis Vincent, Ashish K Khanna

引用次数: 0

Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study. 胰高血糖素样肽-1受体激动剂与酒精使用障碍和糖尿病患者进展为肝硬化和酒精相关入院的关系：一项回顾性队列研究

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1007/s40265-025-02177-x

Feras Al-Moussally, Saud Khan, Vinay Katukuri, Mustafa Kinaan, Ishak A Mansi

{"title":"Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.","authors":"Feras Al-Moussally, Saud Khan, Vinay Katukuri, Mustafa Kinaan, Ishak A Mansi","doi":"10.1007/s40265-025-02177-x","DOIUrl":"10.1007/s40265-025-02177-x","url":null,"abstract":"Aim: In recent years, use of glucagon-like peptide-1 receptor agonists (GLP-1RA) has exponentially increased due to their beneficial effects on weight loss and cardiovascular outcomes. Lately, some animal studies and observational data suggested that GLP-1RA may be useful in the treatment of alcohol use disorder (AUD). We aim to compare the risk of progression to liver cirrhosis and alcohol-related hospital admission after initiation of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4i), as the active comparator, in patients with type 2 diabetes mellitus and AUD.Methods: We conducted a retrospective propensity score-matched cohort study, utilizing new-user and active comparator design. The study used data from the Veterans Health Administration during fiscal years 2006 to 2021 encompassing adults with AUD who initiated either GLP-1RA or DPP4i prescriptions. Our two co-primary outcomes were progression to cirrhosis (compensated and decompensated cirrhosis) and alcohol-related hospital admission.Results: The eligible cohort included 9965 GLP-1RA users and 19,688 DPP4i users. After propensity score matching, 7302 pairs were matched on 79 characteristics without residual imbalances. In the propensity score-matched cohort, progression to cirrhosis occurred in 6.6% of GLP-1RA users and 6.0% DPP4i users; odds ratio (OR): 1.1, 95% confidence interval (95% CI): 0.97-1.26. Alcohol-related hospital admission occurred in 1.4% of GLP-1RA users and in 1.7% of DPP4i users (OR: 0.85; 95% CI: 0.65-1.11).Conclusions: Use of GLP-1RA in patients with AUD was not associated with beneficial effect on progression to cirrhosis or alcohol-related hospital admission.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"813-825"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differentiating IL-23 Inhibitors in Crohn's Disease. 克罗恩病中IL-23抑制剂的鉴别

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1007/s40265-025-02183-z

Olga Maria Nardone, Sudheer K Vuyyuru, Yuhong Yuan, Jurij Hanzel, Vipul Jairath

{"title":"Differentiating IL-23 Inhibitors in Crohn's Disease.","authors":"Olga Maria Nardone, Sudheer K Vuyyuru, Yuhong Yuan, Jurij Hanzel, Vipul Jairath","doi":"10.1007/s40265-025-02183-z","DOIUrl":"10.1007/s40265-025-02183-z","url":null,"abstract":"Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory bowel disease (IBD). Therapies targeting the p19 subunit of IL-23 have recently expanded the therapeutic options for IBD demonstrating efficacy and safety for the treatment of moderate to severe Crohn's disease (CD). Thus, in this review, we provide an overview of agents targeting the IL-23 pathway in CD, highlighting similarities and differences of specific IL-23 inhibitors. Furthermore, we summarize key phase 3 trials and head-to-head trials, focusing on design features and interpretation. Finally, we discuss the positioning of selective IL-23 agents for CD treatment along with areas of unmet clinical needs. However, real-world data will offer additional comparative effectiveness information, data for disease subtypes, and insights into the long-term outcomes of IL-23 inhibition. Looking ahead, ongoing phase 3 studies testing p19-specific selective IL-23 inhibitors are expected to expand the therapeutic options for patients with complex phenotypes, including those with extraintestinal manifestations (EIMs), fistulas, and strictures. Advances in molecular and cellular characterization, including the development of predictive molecular biomarkers, may help guide clinical decision-making, enabling more personalized treatment approaches. Precision medicine studies may further enhance our understanding of the molecular biology of IL-23, shedding light on how these agents work in complex CD and clarify their potential complementary or synergistic effects with other therapies.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"725-740"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0